[
  {
    "ts": "2025-09-23T23:02:01+00:00",
    "headline": "Johnson & Johnson (JNJ) Gains FDA Nod for Subcutaneous Tremfya in Ulcerative Colitis",
    "summary": "In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Johnson & Johnson is one of them. Johnson & Johnson (NYSE:JNJ), a global healthcare leader, continues to strengthen its pharmaceuticals and immunology portfolio while delivering strong stock performance in 2025. This month, the company received […]",
    "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-gains-fda-230201331.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "568e17d3-c52d-3400-8d96-d8dc174cdd43",
      "content": {
        "id": "568e17d3-c52d-3400-8d96-d8dc174cdd43",
        "contentType": "STORY",
        "title": "Johnson & Johnson (JNJ) Gains FDA Nod for Subcutaneous Tremfya in Ulcerative Colitis",
        "description": "",
        "summary": "In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Johnson & Johnson is one of them. Johnson & Johnson (NYSE:JNJ), a global healthcare leader, continues to strengthen its pharmaceuticals and immunology portfolio while delivering strong stock performance in 2025. This month, the company received […]",
        "pubDate": "2025-09-23T23:02:01Z",
        "displayTime": "2025-09-23T23:02:01Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/a064853e8ae32f3fc68f2ca03dab9b6d",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Johnson & Johnson (JNJ) Gains FDA Nod for Subcutaneous Tremfya in Ulcerative Colitis",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_Y_yAZooYuZGdzVSM2FiBQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/a064853e8ae32f3fc68f2ca03dab9b6d.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/63um3EjQCbaSXsLo_I7EDg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/a064853e8ae32f3fc68f2ca03dab9b6d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-gains-fda-230201331.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-gains-fda-230201331.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-23T18:53:00+00:00",
    "headline": "These Dividend Stocks Have Big Yields and Are Beating the Odds",
    "summary": "Income is lagging growth this year. But companies like Seagate, Newmont, Tapestry and CVS offer the best of both worlds: solid dividend yields and strong stock performance.",
    "url": "https://www.barrons.com/articles/dividend-stocks-big-yields-seagate-newsmont-tapestry-cvs-a1384d06?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "3999297d-8e3b-3f5b-b412-d78383e0d856",
      "content": {
        "id": "3999297d-8e3b-3f5b-b412-d78383e0d856",
        "contentType": "STORY",
        "title": "These Dividend Stocks Have Big Yields and Are Beating the Odds",
        "description": "",
        "summary": "Income is lagging growth this year. But companies like Seagate, Newmont, Tapestry and CVS offer the best of both worlds: solid dividend yields and strong stock performance.",
        "pubDate": "2025-09-23T18:53:00Z",
        "displayTime": "2025-09-23T18:53:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/3999297d-8e3b-3f5b-b412-d78383e0d856/these-dividend-stocks-have.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/578e0435c686c5bff109ef635c1b4723",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Gaxpbo3lAuISLQVWPSWwIg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/578e0435c686c5bff109ef635c1b4723.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UXeP6zt4Z54.bSQvpqv3Sw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/578e0435c686c5bff109ef635c1b4723.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/dividend-stocks-big-yields-seagate-newsmont-tapestry-cvs-a1384d06?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            },
            {
              "symbol": "CAH"
            },
            {
              "symbol": "DGRO"
            },
            {
              "symbol": "SDY"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "AVGO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-23T12:00:00+00:00",
    "headline": "Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%",
    "summary": "Important ophthalmic treatment for patients and expected to be a key growth driver for Amneal’s Affordable Medicines segmentBRIDGEWATER, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Abbreviated New Drug Application (ANDA) for bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL and 7.5 mL). The product is the generic equivalent of LUMIGAN® (bimatoprost o",
    "url": "https://finance.yahoo.com/news/amneal-receives-u-fda-approval-120000001.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "c8278842-c4ad-38de-886f-b5f0f13faa4c",
      "content": {
        "id": "c8278842-c4ad-38de-886f-b5f0f13faa4c",
        "contentType": "STORY",
        "title": "Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%",
        "description": "",
        "summary": "Important ophthalmic treatment for patients and expected to be a key growth driver for Amneal’s Affordable Medicines segmentBRIDGEWATER, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Abbreviated New Drug Application (ANDA) for bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL and 7.5 mL). The product is the generic equivalent of LUMIGAN® (bimatoprost o",
        "pubDate": "2025-09-23T12:00:00Z",
        "displayTime": "2025-09-23T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/4ef791be3a2f9474e065b2685657b811",
          "originalWidth": 1176,
          "originalHeight": 523,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IKyNav9GQ9ogucPWSYDjpA--~B/aD01MjM7dz0xMTc2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/4ef791be3a2f9474e065b2685657b811.cf.webp",
              "width": 1176,
              "height": 523,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Vhb7d4stZ8zkWXJ.vAyibQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/4ef791be3a2f9474e065b2685657b811.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amneal-receives-u-fda-approval-120000001.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amneal-receives-u-fda-approval-120000001.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMRX"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-23T09:00:00+00:00",
    "headline": "Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality",
    "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the roll-out of SKINVIVE by JUVÉDERM® in 35 additional markets this year bringing the total to 57 globally in 2025. This expansion underscores Allergan Aesthetics' global strategic commitment to enhancing skin quality worldwide.",
    "url": "https://finance.yahoo.com/news/allergan-aesthetics-announces-expansion-skinvive-090000929.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "4788bf5e-4d70-39ba-af5f-95dd616ecc37",
      "content": {
        "id": "4788bf5e-4d70-39ba-af5f-95dd616ecc37",
        "contentType": "STORY",
        "title": "Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality",
        "description": "",
        "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the roll-out of SKINVIVE by JUVÉDERM® in 35 additional markets this year bringing the total to 57 globally in 2025. This expansion underscores Allergan Aesthetics' global strategic commitment to enhancing skin quality worldwide.",
        "pubDate": "2025-09-23T09:00:00Z",
        "displayTime": "2025-09-23T09:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/d07e572eaef73a27c1ae25977c221fa1",
          "originalWidth": 400,
          "originalHeight": 97,
          "caption": "Allergan Aesthetics (PRNewsfoto/AbbVie)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MH397jf1hFpom1ubHv7ehw--~B/aD05Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/d07e572eaef73a27c1ae25977c221fa1.cf.webp",
              "width": 400,
              "height": 97,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MVOcqHLns2ItUvl7Ea1eaA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/d07e572eaef73a27c1ae25977c221fa1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/allergan-aesthetics-announces-expansion-skinvive-090000929.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/allergan-aesthetics-announces-expansion-skinvive-090000929.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-23T01:20:00+00:00",
    "headline": "1 Top Dividend Stock to Buy and Hold Forever",
    "summary": "The stock has outperformed the broader market since its 2013 IPO, and can still do so over the long run.",
    "url": "https://www.fool.com/investing/2025/09/22/1-top-dividend-stock-to-buy-and-hold-forever/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "a5fce256-5e6f-32a1-b4bc-44b8e35a6526",
      "content": {
        "id": "a5fce256-5e6f-32a1-b4bc-44b8e35a6526",
        "contentType": "STORY",
        "title": "1 Top Dividend Stock to Buy and Hold Forever",
        "description": "",
        "summary": "The stock has outperformed the broader market since its 2013 IPO, and can still do so over the long run.",
        "pubDate": "2025-09-23T01:20:00Z",
        "displayTime": "2025-09-23T01:20:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/d65755b049dae812d2a2742ba09423d2",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Physician talking to patient.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4fnHmK4g..a.QYHMpYMo6w--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/d65755b049dae812d2a2742ba09423d2.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/p8enSNONCNJbTsImJ0jumw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/d65755b049dae812d2a2742ba09423d2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/09/22/1-top-dividend-stock-to-buy-and-hold-forever/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-top-dividend-stock-buy-012000166.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]